Endo Pharmaceuticals Holdings Inc (ENDP) 94.09 $ENDP
28.8% Return Seen to Date on SmarTrend Endo Pharmaceuticals Call (ENDP)
Comtex SmarTrend(R) - Tue Apr 21, 11:28AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.98. In approximately 4 months, Endo Pharmaceuticals has returned 28.78% as of today's recent price of $95.26.
ENDP: 94.09 (-1.09)
Lipocine: A Favorable Risk/Reward Profile
Emerging Equities - at Seeking Alpha - Mon Apr 20, 6:22AM CDT
ENDP: 94.09 (-1.09), LPCN: 7.20 (-0.06)
Endo Pharmaceuticals Has Returned 26.3% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Tue Apr 14, 9:51AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.98. In approximately 4 months, Endo Pharmaceuticals has returned 26.29% as of today's recent price of $93.42.
ENDP: 94.09 (-1.09)
Autohome, Other Foreign Stock Leaders Seen Posting Big Q1
at Investor's Business Daily - Mon Apr 13, 4:17PM CDT
With earnings season now upon us, analysts see profit for the S&P 500 getting dinged by the energy sector. But a number of top-rated foreign stocks are slated to deliver big profit growth. Analysts polled by Thomson Reuters see Autohome's (ATHM)...
ENDP: 94.09 (-1.09), VRX: 206.93 (-3.92), JAZZ: 186.13 (-0.41), FLTX: 47.90 (+0.56), ATHM: 52.09 (+0.08)
Endo Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Tue Apr 07, 4:25PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $89.91 to a high of $91.90. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $90.61 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 94.09 (-1.09)
Endo Pharmaceuticals Up 22.8% Since SmarTrend Uptrend Call (ENDP)
Comtex SmarTrend(R) - Tue Apr 07, 9:25AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.97. In approximately 3 months, Endo Pharmaceuticals has returned 22.78% as of today's recent price of $90.83.
ENDP: 94.09 (-1.09)
These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter
at The Street - Thu Apr 02, 12:41PM CDT
Health care is a hot investment sector, but some of the industry's best performers last quarter included well-known big benefits companies.
MNK: 122.95 (-2.22), CI: 130.25 (-0.45), BSX: 18.41 (+0.10), ENDP: 94.09 (-1.09), BIIB: 423.57 (+1.46), ANTM: 152.84 (-0.04), ABC: 113.81 (-0.08), AET: 107.95 (-0.41), HSP: 87.80 (+0.04), HUM: 180.01 (-0.12)
First Quarter Large Cap Winners And Losers
Bespoke Investment Group - at Seeking Alpha - Thu Apr 02, 1:40AM CDT
The first quarter came to a close Tuesday, and although US indices were flat to modestly positive, there were plenty of big moves throughout the quarter for both the market and individual stocks. The table below lists the 25 best and worst...
MNST: 139.91 (+0.06), KSS: 75.91 (+0.96), CNX: 30.02 (+0.53), EA: 59.81 (+0.78), KSU: 106.24 (+1.07), WYNN: 129.07 (+2.30), KRFT: 88.25 (-0.22), RL: 136.39 (+0.44), HSP: 87.80 (+0.04), PVH: 103.33 (-0.39), BSX: 18.41 (+0.10), NOV: 53.93 (+0.80), VLO: 59.35 (+1.02), DO: 30.07 (-0.02), FOSL: 82.49 (+0.68), MAT: 28.36 (+1.14), FTI: 40.56 (+2.83), MNK: 122.95 (-2.22), MU: 29.50 (+0.95), HAR: 144.53 (+1.29), SWKS: 96.83 (+1.41), PFE: 34.93 (+0.04), VMC: 80.91 (-0.46), STX: 58.23 (-0.18), TIF: 85.10 (+0.95), URBN: 42.17 (+0.03), FSLR: 63.88 (+0.77), NFX: 37.77 (+0.79), AA: 13.57 (+0.05), ESV: 24.03 (+0.13), SNDK: 68.48 (+0.56), BIIB: 423.57 (+1.46), GMCR: 114.53 (+2.27), FCX: 20.57 (+0.34), HUM: 180.01 (-0.12), ANTM: 152.84 (-0.04), RIG: 16.85 (-0.18), CHK: 14.41 (-0.16), HBI: 34.12 (+0.23), JOY: 39.88 (+0.26), MLM: 137.24 (-1.13), ENDP: 94.09 (-1.09), AXP: 78.44 (+1.16), WDC: 100.31 (+0.63), HPQ: 33.51 (+0.30), CI: 130.25 (-0.45), NFLX: 557.68 (-2.76), ABC: 113.81 (-0.08), TSO: 89.53 (+3.65), KLAC: 60.30 (+0.96), AVGO: 127.89 (+4.79)
BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 3:45PM CDT
BioDelivery's (BDSI) shares plunged 24.3% after its painful diabetic neuropathy candidate failed to achieve statistical significance in a phase III study.
BDSI: 9.26 (+0.12), LCI: 66.45 (-0.28), ENDP: 94.09 (-1.09), CBM: 42.07 (-0.65)
George Soros Might Invest $1 Billion in Ukraine -- Here's Where Else He's Investing
at The Street - Tue Mar 31, 9:01AM CDT
George Soros said this week that he is ready to pour $1 billion in Ukraine. With a $24 billion personal fortune, he can certainly afford it.
ENDP: 94.09 (-1.09), SPY: 210.63 (+1.03), LYB: 97.11 (+0.56), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), YPF: 29.75 (+0.81), INTC: 32.70 (+0.27), AAPL: 128.62 (+1.71), CTXS: 64.77 (+0.55), BABA: 82.05 (-0.37)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 94.09 (-1.09), ACT: 295.22 (+0.69), AUXL: 36.47 (-0.06), LLY: 72.30 (+0.09), ABBV: 64.52 (+0.91), CBRX: 7.36 (+0.45), ATRS: 2.78 (unch)
Endo Pharmaceuticals Rises 1.65% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Mar 30, 5:19PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $90.16 to a high of $91.92. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $90.51 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 94.09 (-1.09)
Uptrend Call Working As Endo Pharmaceuticals Stock Rises 23.3% (ENDP)
Comtex SmarTrend(R) - Mon Mar 30, 11:21AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.97. In approximately 3 months, Endo Pharmaceuticals has returned 23.33% as of today's recent price of $91.23.
ENDP: 94.09 (-1.09)
Post-Earnings Briefing - Endo International
PR Newswire - Mon Mar 30, 8:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENDP: 94.09 (-1.09)
Hyperion Therapeutics is an attractive takeover target says analyst
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 3:16PM CDT
ENDP: 94.09 (-1.09), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), HPTX: 45.96 (-0.18)
Mylan Is One Of The Most Undervalued Generic Companies
Max Grigoryev - at Seeking Alpha - Thu Mar 26, 7:36AM CDT
ENDP: 94.09 (-1.09), ABT: 48.35 (+1.23), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Watch for Endo Pharmaceuticals to Potentially Rebound After Falling 1.43% Yesterday
Comtex SmarTrend(R) - Tue Mar 24, 4:22PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $89.17 to a high of $92.64. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $90.80 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 94.09 (-1.09)
Endo Pharmaceuticals Shares Up 24.6% Since SmarTrend's Buy Recommendation (ENDP)
Comtex SmarTrend(R) - Mon Mar 23, 10:01AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.97. In approximately 3 months, Endo Pharmaceuticals has returned 24.57% as of today's recent price of $92.15.
ENDP: 94.09 (-1.09)
Drug Stocks Are Hot: Meet The 5 Best On The IBD 50
at Investor's Business Daily - Sat Mar 21, 7:02AM CDT
Today's IBD 50 roundup features five top drugmakers that have been making headlines. Even though they've all now extended past buying range, they may yet form new bases, and investors won't want to be late to blink-and-you'll-miss-it key price...
ENDP: 94.09 (-1.09), BIIB: 423.57 (+1.46), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), AKRX: 53.70 (-1.69), SLXP: 172.96 (+0.15)
28.8% Return Seen to Date on SmarTrend Endo Pharmaceuticals Call (ENDP)
Comtex SmarTrend(R) - Tue Apr 21, 11:28AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.98. In approximately 4 months, Endo Pharmaceuticals has returned 28.78% as of today's recent price of $95.26.
ENDP: 94.09 (-1.09)
Lipocine: A Favorable Risk/Reward Profile
Emerging Equities - at Seeking Alpha - Mon Apr 20, 6:22AM CDT
ENDP: 94.09 (-1.09), LPCN: 7.20 (-0.06)
Endo Pharmaceuticals Has Returned 26.3% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Tue Apr 14, 9:51AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.98. In approximately 4 months, Endo Pharmaceuticals has returned 26.29% as of today's recent price of $93.42.
ENDP: 94.09 (-1.09)
Autohome, Other Foreign Stock Leaders Seen Posting Big Q1
at Investor's Business Daily - Mon Apr 13, 4:17PM CDT
With earnings season now upon us, analysts see profit for the S&P 500 getting dinged by the energy sector. But a number of top-rated foreign stocks are slated to deliver big profit growth. Analysts polled by Thomson Reuters see Autohome's (ATHM)...
ENDP: 94.09 (-1.09), VRX: 206.93 (-3.92), JAZZ: 186.13 (-0.41), FLTX: 47.90 (+0.56), ATHM: 52.09 (+0.08)
Endo Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Tue Apr 07, 4:25PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $89.91 to a high of $91.90. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $90.61 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 94.09 (-1.09)
Endo Pharmaceuticals Up 22.8% Since SmarTrend Uptrend Call (ENDP)
Comtex SmarTrend(R) - Tue Apr 07, 9:25AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.97. In approximately 3 months, Endo Pharmaceuticals has returned 22.78% as of today's recent price of $90.83.
ENDP: 94.09 (-1.09)
These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter
at The Street - Thu Apr 02, 12:41PM CDT
Health care is a hot investment sector, but some of the industry's best performers last quarter included well-known big benefits companies.
MNK: 122.95 (-2.22), CI: 130.25 (-0.45), BSX: 18.41 (+0.10), ENDP: 94.09 (-1.09), BIIB: 423.57 (+1.46), ANTM: 152.84 (-0.04), ABC: 113.81 (-0.08), AET: 107.95 (-0.41), HSP: 87.80 (+0.04), HUM: 180.01 (-0.12)
First Quarter Large Cap Winners And Losers
Bespoke Investment Group - at Seeking Alpha - Thu Apr 02, 1:40AM CDT
The first quarter came to a close Tuesday, and although US indices were flat to modestly positive, there were plenty of big moves throughout the quarter for both the market and individual stocks. The table below lists the 25 best and worst...
MNST: 139.91 (+0.06), KSS: 75.91 (+0.96), CNX: 30.02 (+0.53), EA: 59.81 (+0.78), KSU: 106.24 (+1.07), WYNN: 129.07 (+2.30), KRFT: 88.25 (-0.22), RL: 136.39 (+0.44), HSP: 87.80 (+0.04), PVH: 103.33 (-0.39), BSX: 18.41 (+0.10), NOV: 53.93 (+0.80), VLO: 59.35 (+1.02), DO: 30.07 (-0.02), FOSL: 82.49 (+0.68), MAT: 28.36 (+1.14), FTI: 40.56 (+2.83), MNK: 122.95 (-2.22), MU: 29.50 (+0.95), HAR: 144.53 (+1.29), SWKS: 96.83 (+1.41), PFE: 34.93 (+0.04), VMC: 80.91 (-0.46), STX: 58.23 (-0.18), TIF: 85.10 (+0.95), URBN: 42.17 (+0.03), FSLR: 63.88 (+0.77), NFX: 37.77 (+0.79), AA: 13.57 (+0.05), ESV: 24.03 (+0.13), SNDK: 68.48 (+0.56), BIIB: 423.57 (+1.46), GMCR: 114.53 (+2.27), FCX: 20.57 (+0.34), HUM: 180.01 (-0.12), ANTM: 152.84 (-0.04), RIG: 16.85 (-0.18), CHK: 14.41 (-0.16), HBI: 34.12 (+0.23), JOY: 39.88 (+0.26), MLM: 137.24 (-1.13), ENDP: 94.09 (-1.09), AXP: 78.44 (+1.16), WDC: 100.31 (+0.63), HPQ: 33.51 (+0.30), CI: 130.25 (-0.45), NFLX: 557.68 (-2.76), ABC: 113.81 (-0.08), TSO: 89.53 (+3.65), KLAC: 60.30 (+0.96), AVGO: 127.89 (+4.79)
BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 3:45PM CDT
BioDelivery's (BDSI) shares plunged 24.3% after its painful diabetic neuropathy candidate failed to achieve statistical significance in a phase III study.
BDSI: 9.26 (+0.12), LCI: 66.45 (-0.28), ENDP: 94.09 (-1.09), CBM: 42.07 (-0.65)
George Soros Might Invest $1 Billion in Ukraine -- Here's Where Else He's Investing
at The Street - Tue Mar 31, 9:01AM CDT
George Soros said this week that he is ready to pour $1 billion in Ukraine. With a $24 billion personal fortune, he can certainly afford it.
ENDP: 94.09 (-1.09), SPY: 210.63 (+1.03), LYB: 97.11 (+0.56), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), YPF: 29.75 (+0.81), INTC: 32.70 (+0.27), AAPL: 128.62 (+1.71), CTXS: 64.77 (+0.55), BABA: 82.05 (-0.37)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone ENDP: 94.09 (-1.09), ACT: 295.22 (+0.69), AUXL: 36.47 (-0.06), LLY: 72.30 (+0.09), ABBV: 64.52 (+0.91), CBRX: 7.36 (+0.45), ATRS: 2.78 (unch)
Endo Pharmaceuticals Rises 1.65% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Mar 30, 5:19PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $90.16 to a high of $91.92. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $90.51 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 94.09 (-1.09)
Uptrend Call Working As Endo Pharmaceuticals Stock Rises 23.3% (ENDP)
Comtex SmarTrend(R) - Mon Mar 30, 11:21AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.97. In approximately 3 months, Endo Pharmaceuticals has returned 23.33% as of today's recent price of $91.23.
ENDP: 94.09 (-1.09)
Post-Earnings Briefing - Endo International
PR Newswire - Mon Mar 30, 8:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENDP: 94.09 (-1.09)
Hyperion Therapeutics is an attractive takeover target says analyst
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 3:16PM CDT
ENDP: 94.09 (-1.09), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), HPTX: 45.96 (-0.18)
Mylan Is One Of The Most Undervalued Generic Companies
Max Grigoryev - at Seeking Alpha - Thu Mar 26, 7:36AM CDT
ENDP: 94.09 (-1.09), ABT: 48.35 (+1.23), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Watch for Endo Pharmaceuticals to Potentially Rebound After Falling 1.43% Yesterday
Comtex SmarTrend(R) - Tue Mar 24, 4:22PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $89.17 to a high of $92.64. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $90.80 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 94.09 (-1.09)
Endo Pharmaceuticals Shares Up 24.6% Since SmarTrend's Buy Recommendation (ENDP)
Comtex SmarTrend(R) - Mon Mar 23, 10:01AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on December 29th, 2014 at $73.97. In approximately 3 months, Endo Pharmaceuticals has returned 24.57% as of today's recent price of $92.15.
ENDP: 94.09 (-1.09)
Drug Stocks Are Hot: Meet The 5 Best On The IBD 50
at Investor's Business Daily - Sat Mar 21, 7:02AM CDT
Today's IBD 50 roundup features five top drugmakers that have been making headlines. Even though they've all now extended past buying range, they may yet form new bases, and investors won't want to be late to blink-and-you'll-miss-it key price...
ENDP: 94.09 (-1.09), BIIB: 423.57 (+1.46), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), AKRX: 53.70 (-1.69), SLXP: 172.96 (+0.15)
